Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Inomata, Minoru ^a   Kamio, Koichiro ^a   Azuma, Arata ^a   Matsuda, Kuniko ^a   Kokuho, Nariaki ^a   Miura, Yukiko ^a   Hayashi, Hiroki ^a   Nei, Takahito ^a   Fujita, Kazue ^a   Saito, Yoshinobu ^a   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Chemokine; Fibrocyte; Idiopathic pulmonary fibrosis; Pirfenidone

Indexed keywords

BLEOMYCIN; PIRFENIDONE; PYRIDONE DERIVATIVE;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; FIBROBLAST; LUNG; LUNG FIBROSIS; MOUSE; PATHOLOGY;

ANIMALS; BLEOMYCIN; CELLS, CULTURED; FEMALE; FIBROBLASTS; LUNG; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; PYRIDONES;

EID: 84894278927     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-16     Document Type: Article

References (46)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824. 10.1164/rccm.2009-040GL, 21471066.
2. Lynch JP, Saggar R, Weigt SS, Zisman DA, White ES. Usual interstitial pneumonia. Semin Respir Crit Care Med 2006, 27:634-651. 10.1055/s-2006-957335, 17195140.
3. Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 2009, 175:3-16. 10.2353/ajpath.2009.081170, 2708789, 19497999.
4. Ebihara Y, Masuya M, Larue AC, Fleming PA, Visconti RP, Minamiguchi H, Drake CJ, Ogawa M. Hematopoietic origins of fibroblasts: II. In vitro studies of fibroblasts, CFU-F, and fibrocytes. Exp Hematol 2006, 34:219-229. 10.1016/j.exphem.2005.10.008, 16459190.
5. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004, 36:598-606. 10.1016/j.biocel.2003.10.005, 15010326.
6. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001, 166:7556-7562.
7. Chesney J, Metz C, Stavitsky AB, Bacher M, Bucala R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 1998, 160:419-425.
8. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179:588-594. 10.1164/rccm.200810-1534OC, 19151190.
9. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047. 10.1164/rccm.200404-571OC, 15665326.
10. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829. 10.1183/09031936.00005209, 19996196.
11. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008, 590:400-408. 10.1016/j.ejphar.2008.06.046, 18598692.
12. Inomata M, et al. Pirfenidone inhibits bone marrow-derived fibrocytes influx into the lungs in bleomycin-induced murine pulmonary fibrosis. Am J Respir Crit Care Med 2013, A5412.
13. Harrison JH, Lazo JS. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 1987, 243:1185-1194.
14. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004, 114:438-446. 10.1172/JCI200420997, 484979, 15286810.
15. Song JS, Kang CM, Kang HH, Yoon HK, Kim YK, Kim KH, Moon HS, Park SH. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med 2010, 42:465-472. 10.3858/emm.2010.42.6.048, 2892600, 20498529.
16. Ishida Y, Kimura A, Kondo T, Hayashi T, Ueno M, Takakura N, Matsushima K, Mukaida N. Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. Am J Pathol 2007, 170:843-854. 10.2353/ajpath.2007.051213, 1864886, 17322370.
17. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005, 166:675-684. 10.1016/S0002-9440(10)62289-4, 1780139, 15743780.
18. Li YJ, Azuma A, Usuki J, Abe S, Matsuda K, Sunazuka T, Shimizu T, Hirata Y, Inagaki H, Kawada T, et al. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts. Respir Res 2006, 7:16. 10.1186/1465-9921-7-16, 1434738, 16438734.
19. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988, 41:467-470. 10.1136/jcp.41.4.467, 1141479, 3366935.
20. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005, 171:1279-1285. 10.1164/rccm.200404-531OC, 15735062.
21. Yaekashiwa M, Nakayama S, Ohnuma K, Sakai T, Abe T, Satoh K, Matsumoto K, Nakamura T, Takahashi T, Nukiwa T. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med 1997, 156:1937-1944. 10.1164/ajrccm.156.6.9611057, 9412578.
22. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004, 113:243-252. 10.1172/JCI200418847, 310750, 14722616.
23. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006, 35:175-181. 10.1165/rcmb.2005-0239OC, 2643255, 16543609.
24. Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM, Hunter MG, Bringardner BD, Monick MM, Brigstock DR, Stromberg PC, et al. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176:78-89. 10.1164/rccm.200609-1279OC, 2049062, 17431224.
25. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006, 173:781-792. 10.1164/rccm.200509-1518OC, 16415274.
26. Murray LA, Rosada R, Moreira AP, Joshi A, Kramer MS, Hesson DP, Argentieri RL, Mathai S, Gulati M, Herzog EL, Hogaboam CM. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010, 5:e9683. 10.1371/journal.pone.0009683, 2837381, 20300636.
27. Rollins BJ. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996, 2:198-204. 10.1016/1357-4310(96)88772-7, 8796888.
28. Okuma T, Terasaki Y, Kaikita K, Kobayashi H, Kuziel WA, Kawasuji M, Takeya M. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol 2004, 204:594-604. 10.1002/path.1667, 15538737.
29. Tokura T, Oku H, Tsukamoto Y. [Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis]. Nihon Yakurigaku Zasshi 2009, 134:97-104. 10.1254/fpj.134.97, 19672005.
30. Ekert JE, Murray LA, Das AM, Sheng H, Giles-Komar J, Rycyzyn MA. Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes. Fibrogenesis Tissue Repair 2011, 4:23. 10.1186/1755-1536-4-23, 3206835, 22011363.
31. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, Hunninghake GW. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994, 149:450-454. 10.1164/ajrccm.149.2.8306044, 8306044.
32. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006, 3:364-372. 10.1513/pats.200601-003TK, 16738202.
33. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002, 122:286S-289S. 10.1378/chest.122.6_suppl.286S, 12475801.
34. Lama VN, Phan SH. The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc 2006, 3:373-376. 10.1513/pats.200512-133TK, 2658688, 16738203.
35. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994, 1:71-81. 2229929, 8790603.
36. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011, 20:85-97. 10.1183/09059180.00001111, 21632796.
37. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 291:367-373.
38. Shinoda H, Tasaka S, Fujishima S, Yamasawa W, Miyamoto K, Nakano Y, Kamata H, Hasegawa N, Ishizaka A. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration 2009, 78:285-292. 10.1159/000207617, 19270434.
39. Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J 1999, 14:376-382.
40. Rose CE, Sung SS, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation 2003, 10:273-288. 10.1080/mic.10.3-4.273.288, 12851645.
41. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev 2000, 177:175-184. 10.1034/j.1600-065X.2000.17715.x, 11138774.
42. Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A, Westergren-Thorsson G, Selman M. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008, 40:2129-2140. 10.1016/j.biocel.2008.02.012, 18374622.
43. Xu J, Mora A, Shim H, Stecenko A, Brigham KL, Rojas M. Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol Biol 2007, 37:291-299. 10.1165/rcmb.2006-0187OC, 1994230, 17463394.
44. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W, Sherrill TP, Plieth D, Neilson EG, Blackwell TS, Lawson WE. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2009, 180:657-665. 10.1164/rccm.200903-0322OC, 2753790, 19556518.
45. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010, 43:161-172. 10.1165/rcmb.2009-0031OC, 2937229, 19767450.
46. Mubarak KK, Montes-Worboys A, Regev D, Nasreen N, Mohammed KA, Faruqi I, Hensel E, Baz MA, Akindipe OA, Fernandez-Bussy S, et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J 2012, 39:133-140. 10.1183/09031936.00141010, 21737551.